Anika Therapeutics, Inc. (ANIK) Press Release
Corporate Events
Anika Therapeutics, Inc. Presents at UBS Healthcare Virtual One-on-One Day, Jun-01-2022
2022-05-25 16:46:00
Anika Therapeutics, Inc. Presents at UBS Healthcare Virtual One-on-One Day, Jun-01-2022 . Venue: New York, New York, United States.
Anika Receives FDA 510(k) Clearance for the X-Twist Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio
2022-05-20 11:00:00
Anika Therapeutics, Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for the X-Twist Knotless Fixation System. The X-Twist Knotless Fixation system is a platform of suture anchors designed to be mechanically strong1, easy to use, and support healing for key repairs such as rotator cuff repair. According to SmartTRAK, there were nearly 670,000 rotator cuff procedures performed in 2021, with the majority of these being performed in the ambulatory surgery center. The X-Twist Knotless Fixation System affords surgeons a variety of knotless and knotted soft tissue fixation options in a single anchor platform. The feature-rich design includes venting, intended to support cellular infiltration through the anchor; a double helix thread that allows fast and easy deployment; the ability to support the surgeon’s preferred combination of multiple sliding suture or tape configurations; and the unique X-Spline™ drive technology which provides more torque transfer for easy anchor insertion. In addition to the shoulder, X-Twist has direct applications in a variety of procedures, including in the foot and ankle, and will initially be available in PEEK-Optima. The X-Twist represents the newest innovation within Anika’s Sports Medicine segment focused on the ASC. Combined with Anika’s recent hardware augmentation indication for Tactoset®, its proprietary hyaluronic acid-enhanced injectable bone substitute, the X-Twist clearance differentiates Anika among its competition by enabling it to offer a knotless fixation solution for rotator cuff repair in patients with insufficient bone quality. Anika expects to begin commercializing the X-Twist Knotless Fixation System in the second half of 2022 within the United States.
UBS Investment Bank, UBS Healthcare Virtual One-on-One Day, Jun 01, 2022
2022-05-19 10:02:00
UBS Investment Bank, UBS Healthcare Virtual One-on-One Day, Jun 01, 2022. Venue: New York, New York, United States.
Tranche Update on Anika Therapeutics, Inc. (NasdaqGS:ANIK)'s Equity Buyback Plan announced on May 2, 2019.
2022-05-06 10:04:00
From January 1, 2022 to March 31, 2022, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 590,751 shares, representing 4.15% for $30 million under the buyback announced on May 2, 2019.
Anika Therapeutics, Inc. Provides Revenue Guidance for the Year 2022
2022-05-05 20:05:00
Anika Therapeutics, Inc. provided revenue guidance for the year 2022. The company expects its overall revenue for fiscal year 2022 to be toward the upper end of its guidance range of low to mid-single digit percent growth compared with 2021. Revenue ranges by product family are: Joint Preservation and Restoration up mid-single to low-double digit percent. OA Pain Management up low-single digit percent Non-Orthopedic revenue down approximately 20% due largely to legacy product rationalization.
Anika Therapeutics, Inc. Presents at Sidoti Summer Small Cap Virtual Conference, Jun-15-2022 11:30 AM
2022-04-30 13:00:00
Anika Therapeutics, Inc. Presents at Sidoti Summer Small Cap Virtual Conference, Jun-15-2022 11:30 AM.
Anika Therapeutics, Inc. - Shareholder/Analyst Call
2022-04-27 21:01:00
AGM
Anika Therapeutics, Inc., Annual General Meeting, Jun 08, 2022
2022-04-27 21:01:00
Anika Therapeutics, Inc., Annual General Meeting, Jun 08, 2022, at 09:00 US Eastern Standard Time. Agenda: To consider election of two Class II Directors; to consider amendment of Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan; to consider ratification of appointment of Deloitte & Touche LLP as Anika’s independent auditor for 2022; to consider advisory “say-on-pay” vote on executive compensation; and any other matters that properly come before the Annual Meeting.
Anika Therapeutics, Inc. to Report Q1, 2022 Results on May 05, 2022
2022-04-07 20:05:00
Anika Therapeutics, Inc. announced that they will report Q1, 2022 results After-Market on May 05, 2022
Anika Therapeutics, Inc., Q1 2022 Earnings Call, May 05, 2022
2022-04-07 20:05:00
Anika Therapeutics, Inc., Q1 2022 Earnings Call, May 05, 2022
Anika Therapeutics, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-14-2022 08:00 AM
2022-04-04 20:05:00
Anika Therapeutics, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-14-2022 08:00 AM.
Tranche Update on Anika Therapeutics, Inc. (NasdaqGS:ANIK)'s Equity Buyback Plan announced on May 2, 2019.
2022-03-11 11:12:00
From October 1, 2021 to December 31, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 590,751 shares, representing 4.15% for $30 million under the buyback announced on May 2, 2019.
Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022
2022-02-11 23:04:00
Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.
Sidoti & Company, LLC, Sidoti Summer Small Cap Virtual Conference, Jun 15, 2022 through Jun 16, 2022
2021-12-02 11:46:00
Sidoti & Company, LLC, Sidoti Summer Small Cap Virtual Conference, Jun 15, 2022 through Jun 16, 2022.
Anika Therapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Dec-02-2021
2021-11-18 21:01:00
Anika Therapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Dec-02-2021 . Venue: New York, New York, United States.
Anika Therapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM
2021-11-18 21:01:00
Anika Therapeutics, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM. Speakers: Cheryl R. Blanchard, President, CEO & Director, Michael L. Levitz, Executive VP, CFO & Treasurer.
Anika Therapeutics, Inc. Enters into Third Amendment to Credit Agreement Amending its Existing Revolving Line of Credit Agreement
2021-11-15 12:58:00
On November 12, 2021, Anika Therapeutics, Inc. entered into a Third Amendment to Credit Agreement amending its existing revolving line of credit agreement dated October 24, 2017 with Bank of America, N.A., which revolving line of credit agreement, as amended to date (including by such Third Amendment). Under the amended agreement, Bank of America, N.A. serves as administrative agent, issuer of letters of credit and swingline lender for a $75.0 million senior revolving line of credit with a maturity date of November 12, 2026. Subject to certain conditions, its may request up to an additional $75.0 million in commitments for a maximum aggregate commitment of $150.0 million, subject to the approval of the Revolving Lenders referred to in the Amended Agreement. Loans under the Amended Agreement generally will bear interest at a rate equal to (a) the Bloomberg Short-Term Bank Yield Index, or BSBY, rate plus (b) an additional percentage that will range from 0.25% to 1.00%, based on its consolidated leverage ratio at the time of the borrowings.
Anika Therapeutics, Inc. has filed a Shelf Registration in the amount of $5.415 million.
2021-11-05 00:00:00
Anika Therapeutics, Inc. has filed a Shelf Registration in the amount of $5.415 million. Security Name: Common Stock Securities Offered: 125,000 Transaction Features: ESOP Related Offering
Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2021
2021-11-04 20:12:00
Anika Therapeutics, Inc. revised revenue guidance for the fiscal year 2021. The company expected its overall revenue for fiscal year 2021 to grow 9%-11% year-over year, compared with previous guidance of 11%-14%, primarily due to the increased impact of COVID. This annual revenue growth is driven by Joint Preservation and Restoration growth in the upper-teens percent range with mid-single digit growth in Joint Pain Management. Other revenue is expected to grow mid-single digits for the year.
Anika Appoints Sheryl Conley to Board of Directors
2021-11-01 13:00:00
Anika Therapeutics, Inc. announced that its Board of Directors has appointed Sheryl Conley as independent director, effective October 28, 2021. Sheryl Conley joins the Anika Board of Directors with over 35 years of orthopedic and healthcare industry experience, most recently as President and CEO of OrthoWorx, Inc., and previously as Group President, Americas and Global Brand Management, and Chief Marketing Officer for Zimmer, Inc.Ms. Conley brings extensive orthopedic medical device industry knowledge with a focus on global brand management, marketing, sales, product development and operations. Ms. Conley will serve on the Audit Committee. This appointment brings the total number of independent directors to seven.
Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021
2021-10-25 10:00:00
Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.
Anika Therapeutics, Inc., Q3 2021 Earnings Call, Nov 04, 2021
2021-10-18 13:09:00
Anika Therapeutics, Inc., Q3 2021 Earnings Call, Nov 04, 2021
Anika Therapeutics, Inc. to Report Q3, 2021 Results on Nov 04, 2021
2021-10-18 13:09:00
Anika Therapeutics, Inc. announced that they will report Q3, 2021 results After-Market on Nov 04, 2021
Anika Therapeutics, Inc. Launches the WristMotion® Total Wrist Arthroplasty System at the American Society for Surgery of the Hand Annual Meeting
2021-09-30 13:00:00
Anika Therapeutics, Inc. announced its WristMotion® Total Wrist Arthroplasty (TWA) System was launched at the American Society for Surgery of the Hand (ASSH) 2021 annual meeting in San Francisco, CA. Previously available to select surgeons and patients during a limited launch beginning on June 30, 2021, the WristMotion TWA System is focused on alleviating pain and restoring function of an arthritic wrist joint. The WristMotion TWA System’s novel design maximizes carpal stability and enables rotational freedom, including the “dart thrower’s” motion. Designed in collaboration with Dr. Arnold-Peter C. Weiss and Dr. Randall Culp, the design of the WristMotion TWA System leverages over 12 years of data focused on stability and improving wrist implants for patients by incorporating Anika’s proprietary taper post fixation for long-term stability and anatomic design for the preservation of motion. The WristMotion TWA System is a modular joint preservation system that replaces both the radial and carpal sides of the wrist joint for patients suffering from rheumatoid arthritis, osteoarthritis, or post-traumatic arthritis. The system incorporates Anika’s proven fixation technology in the central carpal taper post design, also used in the WristMotion Hemiarthroplasty System, which has been in clinical use since 2015, with over 2,600 cases performed to date. The WristMotion TWA System also utilizes Anika’s dual curvature design feature in the carpal implant combined with the dorsal flange (or hood) which allows for greater range of extension due to the increased implant surface area. Preclinical robotic testing has demonstrated that the combination of these features provides improved range of motion and rotational freedom compared to competitive devices, consistent with Anika’s design philosophy of preserving the complex kinematics of the native joints. The WristMotion TWA System has been available to select customers during a limited market release starting after the first case was performed by Dr. Weiss on June 30. To-date, the early clinical feedback on instrumentation, surgical technique, and post-operative range of motion has been very positive.
Anika Therapeutics, Inc. Receives an Additional 510(K) Clearance by the Fda for Tactoset® Injectable Bone Substitute
2021-09-14 13:00:00
Anika Therapeutics, Inc. announced that it has received an additional 510(k) clearance by the FDA for Tactoset® Injectable Bone Substitute. This new indication expands the use of Tactoset to include augmentation of hardware and the support of bone fragments during surgical procedures. This expands Tactoset’s addressable market to include augmentation of suture anchor fixation in addition to treatment of skeletal system defects such as insufficiency fractures. Tactoset is a calcium phosphate based, biocompatible bone graft substitute that incorporates Anika’s core hyaluronic acid (HA) technology. The HA component of Tactoset makes the product highly flowable, easily injectable and able to interdigitate trabecular bone architecture with overall improved handling characteristics compared to competitive products. Once injected, Tactoset hardens and mimics the properties of normal trabecular bone initially and remodels into healthy bone over time.
Anika Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-15-2021 02:00 PM
2021-09-07 14:00:00
Anika Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-15-2021 02:00 PM. Venue: New Windsor, United States. Speakers: Cheryl R. Blanchard, President, CEO & Director, Michael L. Levitz, Executive VP, CFO & Treasurer.
Tranche Update on Anika Therapeutics, Inc. (NasdaqGS:ANIK)'s Equity Buyback Plan announced on May 2, 2019.
2021-08-06 10:08:00
From April 1, 2021 to June 30, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 590,751 shares, representing 4.15% for $30 million under the buyback announced on May 2, 2019.
Anika Therapeutics, Inc. has filed a Shelf Registration in the amount of $45.199 million.
2021-08-06 00:00:00
Anika Therapeutics, Inc. has filed a Shelf Registration in the amount of $45.199 million. Security Name: Common Stock Securities Offered: 1,100,000 Transaction Features: ESOP Related Offering
Anika Therapeutics, Inc. has filed a Shelf Registration in the amount of $8.218 million.
2021-08-06 00:00:00
Anika Therapeutics, Inc. has filed a Shelf Registration in the amount of $8.218 million. Security Name: Common Stock Securities Offered: 200,000 Transaction Features: ESOP Related Offering
Anika Therapeutics Eyes on Acquisitions
2021-08-05 21:00:00
Anika Therapeutics, Inc. (NasdaqGS:ANIK) will look for acquisitions. President and Chief Executive Officer Cheryl R. Blanchard said, "we do have an eye towards additional acquisitions, specifically tuck-ins or what we've got our eye on right now. And we're definitely interested. We remain focused on sort of staying in those soft tissue, bone preserving joint and regenerative solutions areas and staying on target in terms of our strategy, but we think there are some opportunities out there to complete some tuck-in acquisitions, and those tuck-ins will simply add to the strategic imperatives that we've already put out there and continue to accelerate our growth opportunities".
Anika Therapeutics, Inc. Revises Earnings Guidance for the Year 2021
2021-08-05 20:05:00
Anika Therapeutics, Inc. revised earnings guidance for the year 2021. The Company expects its overall revenue for fiscal year 2021 to grow 11-14% year-over year, up from its previous guidance of 10-13%.
Anika Therapeutics, Inc. Presents at The UBS Genomics 2.0 and Medtech Innovations Summit 2021, Aug-12-2021
2021-07-26 10:24:00
Anika Therapeutics, Inc. Presents at The UBS Genomics 2.0 and Medtech Innovations Summit 2021, Aug-12-2021 . Venue: Montage Laguna Beach, 30801 S Coast Hwy, Laguna Beach, California, United States.
Anika Therapeutics, Inc. to Report Q2, 2021 Results on Aug 05, 2021
2021-07-19 14:00:00
Anika Therapeutics, Inc. announced that they will report Q2, 2021 results After-Market on Aug 05, 2021
Anika Therapeutics, Inc., Q2 2021 Earnings Call, Aug 05, 2021
2021-07-19 14:00:00
Anika Therapeutics, Inc., Q2 2021 Earnings Call, Aug 05, 2021
Anika Therapeutics, Inc. Presents at Stephens Annual Investment Conference, Dec-03-2021 12:00 PM
2021-07-10 06:42:00
Anika Therapeutics, Inc. Presents at Stephens Annual Investment Conference, Dec-03-2021 12:00 PM. Venue: Omni Nashville Hotel, 250 Fifth Avenue South, Nashville, Tennessee, United States. Speakers: Cheryl R. Blanchard, President, CEO & Director, Michael L. Levitz, Executive VP, CFO & Treasurer.
Anika Therapeutics, Inc. Announces First Anika Wristmotion Total Wrist Arthroplasty Surgery Performed
2021-07-01 13:00:00
Anika Therapeutics, Inc. announced the limited launch and first surgery performed with Anika’s WristMotion Total Wrist Arthroplasty System. The procedure, which is intended to alleviate pain and restore function, mobility, and rotational freedom of an arthritic wrist joint, was completed by Arnold-Peter C. Weiss, M.D. on June 30, 2021 at University Orthopedics in Providence, Rhode Island. The WristMotion TWA System, cleared by the FDA in October 2020, is a modular joint preservation system that replaces both the radial and carpal sides of the wrist joint for patients suffering from rheumatoid arthritis, osteoarthritis, or post-traumatic arthritis. The system incorporates Anika’s proven fixation technology in the central carpal taper post design, also used in the WristMotion Hemiarthroplasty system, which has been in clinical use since 2015, with over 2,600 cases performed to date. This system design is intended to address the concern of carpal loosening as it relates to existing systems on the market today. The WristMotion System also utilizes the Company’s dual curvature design feature in the carpal implant combined with the dorsal flange which allows for greater range of extension due to the increased implant surface area1. Preclinical robotic testing has demonstrated that the combination of these features provides exceptional range of motion and rotational freedom, consistent with the Company’s design philosophy of preserving the complex kinematics of the native joints. The WristMotion TWA System, along with the WristMotion Hemiarthroplasty device, provides surgeons with multiple treatment options for different stages and severities of wrist osteoarthritis. Surgeries with the WristMotion Total Wrist Arthroplasty System will be performed as part of a limited launch in several cities including Birmingham, AL, Jackson, MS, Philadelphia, PA and Providence, RI. The full nationwide launch of the product will commence this Fall with a preview slated for the American Academy of Orthopedic Surgeons annual meeting in August and full market launch at the American Society for Surgery of the Hand annual meeting in late September.
Fundamental Summary
Anika Therapeutics published its Q1 report on 2022-05-05 with positive results, but no significant factors particularly remarkable relative to its peers. We do believe, though, that macro-related market conditions will influence its performance more significantly than its individual results. We therefore gave Anika Therapeutics a total score of 73 out of 100 and a HOLD recommendation.
Anika Therapeutics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 36.69 million compared to USD 34.29 million a year ago. Net loss was USD 2.93 million compared to net income of USD 2.84 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to basic earnings per share from continuing operations of USD 0.2 a year ago. Diluted loss per share from continuing operations was USD 0.2 compared to diluted earnings per share from continuing operations of USD 0.2 a year ago.
Business Description
Anika Therapeutics, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company’s non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics was founded in 1983 and is headquartered in Bedford, Massachusetts.
Sector Overview
Anika Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Anika Therapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | -0.6 | -139.4% | 62 | |
| Net Cashflow | -15.9 | 0.0% | 69 | |
| Capital Expenditure | -2.4 | 0.0% | 70 | |
| Asset Turnover | 0.4 | 2.9% | 51 | |
| Free Cashflow | 0.1 | 0.0% | 67 |
* All values are TTM
The below chart reflects Anika Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Anika Therapeutics's peer average final assessment score stands on 70.0, Anika Therapeutics's score is 73.
- ANIK
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Anika Therapeutics's stock is now priced above its 50-day, but below its 5-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Anika Therapeutics's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 52.
5D MA
22.76
50D MA
21.88
200D MA
31.75
MACD
0.17
RSI
34.29
STOCH
56.91
Balance Sheet Analysis
Overall, Anika Therapeutics's critical balance sheet metrics appear to signal strong support and a high likelihood of positive growth going forward. Anika Therapeutics has done an excellent job managing its liabilities. Anika Therapeutics's liabilities stood at 56.5 in the current filing, which represents a -6.6% change from the previous report. This performance is all interesting relative to their peers and suggests that their stock price has room to grow to reflect a higher intrinsic value. Therefore, we rated their liabilities movement with a score of 76. Also, The company's assets section could set high expectations for Anika Therapeutics's future attractiveness, as they went to 342.2, which is a -1.5% change from the last period. This performance is interesting in comparison to its peers and competitors. Consequently, their asset movement received a grade of 68. However, one discouraging result, Equity, stood out. Anika Therapeutics management produced disappointing equity metrics this period, which stood at 285.8, representing a -0.5% change. This parameter often affects companies in the same industry and market capitalization by up to 3.1%. These metrics are all the more disappointing relative to their peers and should blunt potential positive momentum in its's stock price. Its equity movement component, therefore, received a grade of 63. Because its management is doing an excellent job managing these critical metrics, the balance sheet was given a score of 64.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 342.2 | -1.5% | 68 |
| Liabilities | 56.5 | -6.6% | 76 |
| Price to Book | 1.1 | -37.1% | 65 |
| Cash & Equivalents | 90.3 | -4.3% | 64 |
| Equity | 285.8 | -0.5% | 63 |
The below chart describes Anika Therapeutics's performance as reflected on its balance sheet with respect to its peers. While Anika Therapeutics received a balance sheet score of 64, the average of its peers stands on 70.0.
- ANIK
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 3 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 4 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 5 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 7 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 16 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 18 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 20 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 21 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 22 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 23 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 24 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 25 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 26 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 27 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 28 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 29 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 30 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 31 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 32 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 33 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 34 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 35 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 36 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 37 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 38 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 39 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 40 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 41 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 42 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 43 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 45 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 51 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 53 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 56 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 64 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 65 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 67 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 68 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 77 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 78 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 81 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 89 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 93 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Anika Therapeutics appears likely to maintain its strong income statement metrics, especially EBITDA and Revenue Efficiency. Anika Therapeutics reported impressive EBITDA this period. At filing, EBITDA was reported as 5.7, representing 19.5% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 26.4%. Its EBITDA metrics highlight an impressive overall financial performance, which is expected to continue moving forward. The company's EBITDA movement, therefore, received a grade of 80. Also, Anika Therapeutics's financials reveal an interesting trend for their revenue efficiency. This parameter often affects companies in the same industry and market capitalization by up to 1.9%. Their impressive revenue efficiency is even more impressive relative to its peers and competitors in the current market. Consequently, their revenue efficiency received a grade of 63. That said, one metric, Return Factors, stood out as strongly negative. In this filing, Anika Therapeutics reported a return on equity (ROE) ratio of -0.6, which represents a growth of -139.4%. This metric might have a 3.2 percent impact on companies in the same industry and with the same market capitalization. They does not yet appear to be headed in the right direction regarding these return on equity and return on assets metrics. Its return factors (ROA & ROE) components, therefore, received a grade of 62. their income statement received an overall score of 77.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | 5.7 | 19.5% | 80 |
| Total Revenues | 150.2 | 1.6% | 63 |
| Return on Equity | -0.6 | -139.4% | 62 |
The below chart describes Anika Therapeutics's performance as reflected on its income statement with respect to its peers. While Anika Therapeutics received a income statement score of 77 , the average of its peers stands on 70.0.
- ANIK
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 3 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 4 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 5 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 7 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 16 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 18 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 20 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 21 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 22 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 23 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 24 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 25 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 26 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 27 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 28 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 29 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 30 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 31 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 32 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 33 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 34 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 35 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 36 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 37 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 38 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 39 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 40 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 41 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 42 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 43 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 45 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 51 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 53 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 56 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 64 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 65 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 67 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 68 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 77 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 81 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 89 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 93 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Overall, Anika Therapeutics's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. Anika Therapeutics's management was effective in improving its CapEx, which now sits at -2.4 and represents 0.0% change from the previous report. This remarkable CapEx growth is expected to reinforce upward momentum for its's stock price going forward. Consequently, their CapEx movement received a grade of 70. Also, Anika Therapeutics's strong net cash flow numbers, which were -15.9 in this filing, showed a 0.0% change from the last period. The company is headed in the right direction regarding business priorities, exhibiting prudent net cash flow management and growth. Hence, its net cash flow earned a score of 69. However, one discouraging result, Asset Turnover, stood out. Anika Therapeutics's asset turnover metrics were concerning and highlighted potential issues management is having effectively turning assets into sales efficiently. At filing, their asset turnover metrics were 0.4, representing a 2.9% change from the previous period. Companies in the same sector and market capitalization will usually be affected by up to 11.2 percent by this parameter. Their asset turnover numbers are significantly less impressive when compared to their peers and competitors. Correspondingly, their asset turnover movement received a grade of 51. The company's cash flow received an overall score of 63.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | -15.9 | 0.0% | 69 |
| Capital Expenditure | -2.4 | 0.0% | 70 |
| Asset Turnover | 0.4 | 2.9% | 51 |
| Free Cashflow | 0.1 | 0.0% | 67 |
The below chart describes Anika Therapeutics's performance as reflected on its cash flow with respect to its peers. While Anika Therapeutics received a cash flow score of 63, the average of its peers stands on 67.0.
- ANIK
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 3 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 4 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 5 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 7 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 16 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 18 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 20 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 21 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 22 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 23 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 24 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 25 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 26 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 27 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 28 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 29 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 30 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 31 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 32 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 33 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 34 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 35 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 36 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 37 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 38 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 39 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 40 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 41 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 42 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 43 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 45 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 51 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 53 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 56 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 64 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 65 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 67 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 68 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 77 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 81 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 89 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 93 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.